FOXA1 is an essential pioneer factor which has been shown to be pivotal in the tumour growth, progression and maintenance of oestrogen receptor positive luminal breast cancer. It’s is an area of significant unmet patient need where approximately 30% of patients progress to late stage endocrine resistant disease, and where there is potential for new treatments to have significant impacts for patients not addressed by existing therapeutics.